Although mutations may manifest as either internal tandem duplication of the juxta membrane domain (FLT3-ITD) or point mutations in the tyrosine kinase domain (FLT3TKD), FLT3-ITD is the manifestation more highly associated with a worse prognosis in AML patients, predicting shorter remission and decreased OS [82,83]. The gene discussed is FLT3; the disease is acute myeloid leukemia.